Genome-wide linkage analysis of serum creatinine in three isolated European populations  by Pattaro, Cristian et al.
Genome-wide linkage analysis of serum creatinine in
three isolated European populations
Cristian Pattaro1, Yurii S. Aulchenko2, Aaron Isaacs2, Veronique Vitart3, Caroline Hayward3,
Christopher S. Franklin4, Ozren Polasek5, Ivana Kolcic5, Zrinka Biloglav5, Susan Campbell3, Nick Hastie3,
Gordan Lauc6, Thomas Meitinger7,8, Ben A. Oostra2, Ulf Gyllensten9, James F. Wilson4, Irene Pichler1,
Andrew A. Hicks1, Harry Campbell4, Alan F. Wright3, Igor Rudan4,10, Cornelia M. van Duijn2,
Peter Riegler11, Fabio Marroni1 and Peter P. Pramstaller1,12,13, on behalf of the EUROSPAN Consortium
1Institute of Genetic Medicine, European Academy Bozen/Bolzano (EURAC), Bolzano, Italy – Affiliated Institute of the University of
Lu¨beck, Lu¨beck, Germany; 2Genetic Epidemiology Unit, Departments of Epidemiology and Biostatistics, Clinical Genetics, and
Forensic Molecular Biology, Erasmus University Medical Center, Rotterdam, The Netherlands; 3MRC Human Genetics Unit, Institute
of Genetics and Molecular Medicine, Edinburgh, UK; 4Centre for Population Health Sciences, University of Edinburgh Medical School,
Teviot Place, Edinburgh, Scotland, UK; 5Andrija Stampar School of Public Health, University of Zagreb Medical School, Zagreb, Croatia;
6Department of Biochemistry and Molecular Biology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia;
7Institute of Human Genetics, Technical University of Munich, Munich, Germany; 8Institute of Human Genetics, Helmholtz Zentrum
Mu¨nchen, German Research Center for Environmental Health, Neuherberg, Germany; 9Department of Genetics and Pathology, Rudbeck
Laboratory, Uppsala University, Uppsala, Sweden; 10Croatian Centre for Global Health, University of Split Medical School, Soltanska 2,
Split, Croatia; 11Division of Nephrology and Hemodialysis, Central Hospital, Bolzano, Italy; 12Department of Neurology, University of
Lu¨beck, Lu¨beck, Germany and 13Department of Neurology, Central Hospital, Bolzano, Italy
There is increasing evidence for a role of genetic
predisposition in the etiology of kidney disease, but linkage
scans have been poorly replicated. Here we performed a
genome-wide linkage analysis of serum creatinine on 2859
individuals from isolated villages in South Tyrol (Italy),
Rucphen (The Netherlands) and Vis Island (Croatia),
populations that have been stable and permanently resident
in their region. Linkage of serum creatinine levels to loci
on chromosomes 7p14, 9p21, 11p15, 15q15-21, 16p13, and
18p11 was successfully replicated in at least one discovery
population or in the pooled analysis. A novel locus was found
on chromosome 10p11. Linkage to chromosome 22q13,
independent of diabetes and hypertension, was detected
over a region containing the non-muscle myosin heavy chain
type II isoform A (MYH9) gene (LOD score¼ 3.52). In
non-diabetic individuals, serum creatinine was associated
with this gene in two of the three populations and in
meta-analysis (SNP rs11089788, P-value¼ 0.0089). In
populations sharing a homogeneous environment and genetic
background, heritability of serum creatinine was higher than
in outbred populations, with consequent detection of a larger
number of loci than reported before. Our finding of a
replicated association of serum creatinine with the MYH9
gene, recently linked to pathological renal conditions in
African Americans, suggests that this gene may also
influence kidney function in healthy Europeans.
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It is well established that inherited factors play an important
role in the etiology of renal disease.1 Familial aggregation of
both diabetic and IgA nephropathies has been extensively
recognized,2 and several genetic factors contributing to
chronic renal failure have been proposed.3 The genetic
heritability of serum creatinine (SCR), glomerular filtration
rate (GFR), and creatinine clearance (CrCl) was shown to be
significant and very high, irrespective of ethnicity and
concomitant pathologies.4–11 Recently, several genome-wide
linkage scans have been carried out in the attempt to detect
loci explaining variability of quantitative renal phenotypes in
individuals of different ethnicities,4–7,10–15 including extended
pedigrees of diabetic4,14,15 and hypertensive6,7,12,13 indivi-
duals. Some of these studies assessed linkage of GFR or CrCl,
estimated by means of common SCR-based equations.
16
However, it is worth noting that, when age, sex, and other
factors used for estimation of these quantities are included in
regression models, there is no meaningful difference between
the analysis of estimated GFR (CrCl) and SCR.
In this study, we investigated the genetics of SCR in three
genetically isolated populations living in Europe and
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participating in the European Special Population Research
Network (EUROSPAN). Isolated populations can play an
important role in dissecting complex traits.17,18 One
advantage over outbred populations is related to the greater
homogeneity of lifestyle and environmental factors, as
empirically shown in South Tyrolean isolates.19 Population
isolates are characterized by a reduced number of recombi-
nation events, typical of pedigrees generated from a small
group of founders. Thus, the study of small isolates could
facilitate the search for causal loci involved in both
monogenic and polygenic disorders.20–22
RESULTS
The study involved 2859 participants from the MICROS
study (Italy), the Erasmus Rucphen Family (ERF) study (the
Netherlands), and from the island of Vis (Croatia).
Characteristics of participants are reported in Table 1.
Overall, women were slightly more in number than were
men, and Vis participants were 7–9 years older than
other participants. Body mass index was higher in ERF
and Vis study participants than in the MICROS study
participants. ERF had a higher prevalence of ever smokers,
diabetes, hypertension, and higher systolic blood
pressure. Distribution of renal function indicators suggested
a better renal condition in MICROS and ERF than in Vis
participants.
After pedigree splitting, singletons and individuals with
missing information on covariates were eliminated, and
finally, 856, 822, and 561 individuals from MICROS, ERF,
and Vis, respectively, were retained in the analysis. They were
subdivided into 121 (MICROS), 138 (ERF), and 156 (Vis)
smaller pedigrees with a median size of 18 individuals (range:
3–27) in MICROS, 19 (12–28) in ERF, and 5.5 (3–25) in Vis.
The distribution of relative pairs according to study and
genetic relationship is reported in the Supplementary
Information File 1. Given a hypothesized total heritability
of 40%, the pooled sample showed 76% power to detect
a logarithm of odds (LOD) score X1.9 for a quantitative
trait locus with specific heritability of 18%. The pedigrees
from MICROS and ERF cohorts showed substantial power
as well. Most likely because of the small size of split
pedigrees, the power was much reduced in Vis (an overview
of power estimates is given in the Supplementary Informa-
tion File 2).
As depicted in Table 2, genetic heritability (h2) of SCR
was 0.44 in the pooled sample (P-value¼ 1.09 1031), with
a minimum in Vis (h2¼ 0.24, P-value¼ 0.0073) and a
maximum in MICROS (h2¼ 0.53, P-value¼ 1.22 10–17).
The exclusion of diabetics did not affect the estimates. In
MICROS, ERF, and in the pooled sample, h2 increased when
excluding individuals on anti-hypertensive treatment. In
all populations, h2 was higher in non-diabetics not treated for
hypertension. The results were similar under the multi-
variable model (data not shown).
Linkage regions corresponding to a LOD score X1.9
(suggestive linkage) or X3.3 (significant linkage) are
reported in Table 3. A linkage peak was detected in MICROS
on chromosome 7p14 (multivariable LOD score¼ 2.25). Two
peaks (at 46 and 49 cM) were observed on chromosome
9p21 in the pooled analysis (Figure 1). The first peak was
slightly higher when excluding individuals on anti-hyper-
tensive treatment (multivariable LOD score¼ 2.09). Linkage
was more pronounced in the multivariable analysis than
in the sex- and age-adjusted one. On chromosome 10p11,
Table 1 | Characteristics of study participantsa
Study MICROS ERF Vis P-valueb
No. of participants 891 1388 580
Determinants of renal function
Age (years) 47 (16.6) 49 (14.6) 56 (16.2) o0.00001
Sex (F) 487 (54.7) 785 (56.6) 330 (56.9) 0.60232
BMI (kg/m2) 26 (4.5) 27 (4.6) 27 (4.1) o0.00001
Ever smoked (yes) 365 (41.1) 963 (70.3) 294 (50.8) o0.00001
Diabetes (yes) 32 (3.7) 63 (7.4) 35 (6.1) 0.00273
Under anti-hypertensive treatment (yes) 76 (8.5) 284 (34.0) 149 (25.8) o0.00001
SBP (mm Hg) 133 (20.8) 140 (19.8) 137 (23.7) o0.00001
DBP (mm Hg) 80 (11.2) 80 (9.7) 80 (11.4) 0.69550
MAP (mm Hg) 98 (13.5) 100 (11.8) 99 (14.1) 0.00007
Renal function
Males
SCR 0.96 (0.175) 0.97 (0.181) 1.09 (0.22) o0.00001
eGFRc 86 (17.2) 86 (17.9) 75 (17.5) o0.00001
Females
SCR 0.80 (0.175) 0.79 (0.181) 0.91 (0.218) o0.00001
eGFRc 81 (17.2) 81 (17.9) 67 (17.5) o0.00001
BMI, body mass index; DBP, diastolic blood pressure; GFR, glomerular filtration rate; MAP, mean arterial pressure; SCR, serum creatinine; SBP, systolic blood pressure.
aReported data are mean (s.d.) or N (%), depending on the type of study variable.
bUnadjusted homogeneity w2 test for categorical variables. Kruskal–Wallis test for continuous variables.
ceGFR: glomerular filtration rate as estimated with the updated 4-variable modification of diet in renal disease (MDRD) formula.23
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suggestive linkage was detected in ERF in individuals not
treated for hypertension. Much smaller values were observed
when these individuals were included. In the pooled
analysis, we detected linkage on chromosome 11p15 in
individuals not on anti-hypertensive medication (Figure 1).
The signal was similar when diabetics were also removed.
On chromosome 15p15, suggestive linkage was observed in
the ERF sample under both models, and in all subgroup
analyses.
Suggestive linkage to a quantitative trait locus located
on chromosome 16p13 was detected in the MICROS
sample when excluding individuals on anti-hypertensive
treatment, independently of diabetic status (Figure 2). On
chromosome 18p11, the sex- and age-adjusted LOD score
was 2.46 in the ERF cohort. The signal was higher when
excluding diabetics (LOD score¼ 2.69), but disappeared
when removing individuals on anti-hypertensive treat-
ment. Similar results were observed with the multivariable
analysis.
The highest LOD scores were detected on chromosome
22q13 in the MICROS cohort (Figure 2). The first peak, at
45 cM, was observed especially when excluding individuals
treated for hypertension and diabetics (multivariable LOD
score¼ 3.16). The second peak was observed between 61 and
62 cM. The highest LOD score was obtained when omitting
diabetics (LOD score¼ 3.52). Results were consistent and
similar across all subgroup analyses, but signals were smaller
when adjusting for age and sex only. In the same region, the
pooled analysis detected a suggestive linkage peak at 56 cM,
where the signal was of similar magnitude regardless of the
considered subgroup of individuals and the adjustment
applied to the regression model.
Replication of earlier reported linkage findings
To assess the consistency of our results with that which was
earlier described, we carried out a review of the literature,
identifying over 30 articles reporting linkage on SCR, SCR-
derived traits, urinary albumin-to-creatinine ratio, and renal
disease. For our most prominent findings, the comparison
with the literature is reported in Table 3. Apart from the
region on chromosome 10p11 and a part of the large region
on chromosome 22q13, in all other cases, we confirmed
many results reported earlier, and often our findings were
supported by more than one earlier study. When extending
the comparison to all LOD scores X1, the amount of
replication was much larger. Of the 54 detected regions, 38
have been reported earlier. This extensive list is provided in
the Supplementary Information File 3, together with
annotated references to earlier findings.
Association with the non-muscle myosin heavy-chain type II
isoform A gene
The region under the linkage peak at 45 cM on chromosome
22q13 included the non-muscle myosin heavy-chain type II
isoform A gene (MYH9), recently reported to be associated
with nondiabetic end-stage renal disease (ESRD),29 focal
segmental glomerulosclerosis,30 hypertension-associated albu-
minuria,31 and hypertension-associated ESRD32 in African
Americans. Given the availability of single nucleotide
polymorphism (SNP) genotypes for all study participants,
we tested the association of the 22 SNPs available within the
gene and SCR. Results obtained in nondiabetics are reported in
Table 4. When adjusting for age and sex, the reference allele of
SNP rs11089788 was consistently associated with a reduction
in SCR levels in all the three populations, with a meta-analysis
P-value of 0.0089 (the allele was associated with a decrease of
0.0118 mg per 100 ml of SCR levels). A significant association
was also found for SNP rs5756168 (P¼ 0.0127), although this
finding needs to be interpreted with caution given the large
between-study heterogeneity observed. However, rs5756168
was strongly associated with SCR in the MICROS cohort. In
this case, an increment of 0.03 mg per 100 ml of SCR per copy
of the effect allele was observed, with a P-value of 0.0034.
Within the same cohort, another SNP was significantly
associated with SCR (rs2239784, P¼ 0.0294): each copy of
the rare allele conferred a reduction of 0.03 mg per 100 ml. In
the MICROS cohort, the other three SNPs were borderline
significant. In the Vis cohort, the rare allele of SNP rs136211
was associated with a reduction of 0.04 mg per 100 ml
(P¼ 0.0123). When including diabetics in the analysis, results
were confirmed, but were much weaker: the rs11089788 was
associated with SCR, with a P-value of 0.0145. Under
multivariable adjustment, results were also confirmed, but
with a reduced strength (data not shown).
Table 2 | Genetic heritability of serum creatinine
MODEL
All
subjects
Subjects not on anti-
hypertensive treatment
Non-diabetics
only
Subjects without diabetes and not
on anti-hypertensive treatment
Study h2 (s.e.) P-value h2 (s.e.) P-value h2 (s.e.) P-value h2 (s.e.) P-value
ERF 0.44 (0.06) 7.00 1017 0.47 (0.09) 3.48 1008 0.41 (0.06) 4.46 1014 0.48 (0.09) 2.97 1008
Vis 0.24 (0.10) 0.0073 0.21 (0.18) 0.1124 0.25 (0.11) 0.0094 0.31 (0.19) 0.0505
MICROS 0.53 (0.07) 1.22 1017 0.79 (0.09) 2.15 1017 0.52 (0.07) 1.10 1015 0.76 (0.10) 3.32 1016
Total 0.44 (0.04) 1.09 1031 0.53 (0.06) 1.03 1019 0.42 (0.04) 1.74 1027 0.54 (0.06) 1.32 1019
Estimates (h2), s.e., and P-value are reported by study population (ERF, Vis, MICROS, and pooled), and model (all subjects included; subjects not on anti-hypertensive
treatment; non-diabetics only; subjects without diabetes and not on anti-hypertensive treatment).
Polygenic models were adjusted for sex, age, and age2.
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DISCUSSION
With thist study, we confirm that SCR levels are highly
heritable in the general population not selected for any
disease. Furthermore, in the studied isolates, heritability
seemed to be slightly higher than that reported earlier. We
confirm linkage on chromosomes 7p14, 9p21, 11p15, 15q15,
16p13, and 18p11. Novel linkage regions are suggested on
chromosomes 10p11 and 22q13. Within this last region, we
replicated the association of SCR with the MYH9 gene,
recently found to be associated with pathological renal
conditions in African Americans,29–32 in three European
populations.
Subgroup analyses were carried out by excluding diabetics
and individuals on anti-hypertensive treatment. Given that
diabetic nephropathy is the leading cause of renal insuffi-
ciency, the exclusion of diabetics was motivated by the need
to exclude diabetes-related loci. Individuals on treatment for
hypertension were excluded under the hypothesis that they
were probably affected by severe hypertension. Although
known to affect renal function, hypertension could be related
to both genetic and nongenetic causes. Moreover, it is
important to consider that anti-hypertensive medications
could include the renin–angiotensin system antagonists,
drugs that increase the propensity to a normal kidney
Table 3 | Chromosomal regions corresponding to a LOD score X1.9 (suggestive linkagea)
LOD scoree
Nominal Empirical
Chromosomeb cM Closest markersc LOD-1 interval (bp) Population Groupd S-A M S-A M Previous evidence (linkage)
7p14 57 D7S2250-D7S2209 30,080,312–46,082,813 MICROS All 1.95 2.25 1.77 1.86 Linkage to the logarithm of SCR in
hypertensive sibships of black
individuals7 and to eGFR in the
Framingham Heart Study8
7p14 57 D7S2250-D7S2209 30,080,312–46,082,813 MICROS –DM 1.98 2.27 1.81 1.93
9p21 46 D9S171-D9S1679 20,347,873–33,163,684 Pooled –AHT 1.88 2.29 1.69 2.09 Overlap with a linkage peak for
ESRD in black families enriched for
nondiabetic nephropathy24
9p21 46 D9S171-D9S1679 20,347,873–33,163,684 Pooled –AHT and DM 1.84 2.10 1.65 1.94
9p21 49 D9S2154-D9S169 20,347,873–33,163,684 Pooled –AHT and DM 1.72 2.14 1.55 1.98
10p11 61 D10S1654-D10S1217 19,599,223–42,338,905 ERF –AHT 2.15 1.98 2.14 2.05
10p11 61 D10S1654-D10S1217 18,880,109–42,338,905 ERF –AHT and DM 1.91 1.74 2.01 1.69
11p15 33 D11S4106-D11S928 15,494,428–23,559,409 Pooled –AHT 1.91 1.62 1.72 1.45 Within the LOD-1 supporting region
for linkage to eGFRMDRD in African
Americans and in a multiethnic
population15
15q15 44 D15S537-D15S659 34,024,135–53,542,801 ERF ALL 1.94 1.99 1.85 1.86 Within the LOD-1 supporting
interval for linkage to SCR in West
African pedigrees with type II
diabetes.14,25 Linkage to autosomal-
dominant renotubular Fanconi
syndrome,25 which can be related
to muscle weakness26
15q15 44 D15S537-D15S659 33,171,231–53,542,801 ERF –DM 1.98 1.92 1.82 1.82
15q15 44 D15S537-D15S659 36,794,835–53,542,801 ERF –AHT 1.88 1.86 1.88 1.92
15q21 47 D15S123-D15S196 33,171,231–53,542,801 ERF –DM 1.81 1.94 1.66 1.84
15q21 48 D15S1028-D15S119 36,794,835–53,542,801 ERF –AHT 2.04 1.80 2.03 1.87
15q21 48 D15S1028-D15S119 36,794,835–53,542,801 ERF –AHT and DM 2.11 1.93 2.21 1.88
16p13 15 D16S423-D16S3392 4,274,729–8,392,753 MICROS –AHT 2.44 2.48 2.13 2.00 Linkage to early onset ESRD in black
families enriched for nondiabetic
nephropathy;24 LOD score of 2.0 in
a genome-wide scan of UACR in a
diabetic, multiethnic population,
in majority of Caucasians27
16p13 16 D16S423-D16S3392 4,274,729–10,848,100 MICROS –AHT and DM 2.35 2.26 1.95 1.88
18p11 27 D18S1163-D18S843 4,609,789–9,951,551 ERF ALL 2.46 2.59 2.35 2.42 Linkage to GFR estimated by
cystatin C in type II diabetic relative
pairs (D18S843)6
18p11 27 D18S1163-D18S843 4,609,789–9,951,551 ERF –DM 2.69 2.66 2.47 2.53
22q13 45 D22S1045-D22S445 34,736,599–47,788,230 MICROS –AHT 2.49 3.01 2.22 2.42 Overlap with the LOD-1 supporting
interval for linkage to UACR in a
diabetic, multiethnic population,
in majority of Caucasians27
22q13 45 D22S1045-D22S445 32,925,593–47,788,230 MICROS –AHT and DM 2.76 3.16 2.28 2.63
22q13 56 D22S1171-D22S1168 37,415,838–47,556,879 Pooled ALL 1.92 1.89 1.84 1.80
22q13 56 D22S1171-D22S1168 41,383,475–47,556,879 Pooled –AHT 1.89 1.93 1.70 1.76
22q13 56 D22S1171-D22S1168 41,383,475–47,556,879 Pooled –AHT and DM 2.17 2.14 1.95 1.98
22q13 61 D22S532-D22S922 35,593,050–47,788,230 MICROS ALL 2.68 3.43 2.44 2.84
22q13 62 D22S532-D22S922 35,593,050–47,788,230 MICROS –DM 2.85 3.52 2.61 3.00
22q13 62 D22S532-D22S922 34,736,599–47,788,230 MICROS –AHT 2.55 2.98 2.22 2.40
22q13 62 D22S532-D22S922 32,925,593–47,788,230 MICROS –AHT and DM 2.86 3.16 2.37 2.63
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; LOD, logarithm of odds; SCR, serum creatinine; UACR, urinary albumin-to-creatinine ratio.
aUnder Lander and Kruglyak’s guidelines.28
bNCBI Build 36.3, region where the closest marker is located.
cGiven that the three populations had three different maps and the deCODE map was taken as the reference, these are the markers from the deCODE map that are the closest
ones to the location of the maximum LOD score.
dALL, no subjects excluded; –AHT, subjects on anti-hypertensive treatment excluded; –DM, subjects with diabetes excluded; –AHT and DM, subjects on anti-hypertensive
treatment and diabetics excluded.
eNominal and empirical LOD scores estimated under sex- and age-adjusted model (S-A) and multivariable model (M); see the Methods section for details.
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function and could modify SCR toward normal values, with a
consequent reduction of the real variability of the trait. This
would reduce the observed genetic heritability and thus the
power to detect linkage.
Overall, heritability of SCR was similar to that reported
for plasma creatinine in an Australian study on twins34 and
much higher than that reported recently in Americans with
Caucasian ancestors.5,8 Noticeable differences were observed
between the investigated populations, with the lower
heritability of the Vis cohort likely because of the small
size of split pedigrees. A higher heritability was observed
when excluding diabetics and, in particular, individuals
on anti-hypertensive treatment. This finding supports that
heritability of SCR in healthy individuals is substantial and
that the genetic variability of the trait can be better
investigated when the influence of external factors is
removed.
Our genome-wide linkage analysis provides replication of
several linkage loci reported earlier. In many cases, our
findings were supported by multiple earlier studies, in other
cases, our results were the first replication of earlier hits.
Some of the most relevant peaks were located in regions
carrying genes of interest for kidney function or muscle mass
formation. For instance, the LOD-1 interval supporting the
signal on chromosome 7p14 includes the insulin-like growth
factor-binding protein 1 gene (IGFBP1), associated with
impaired renal function in diabetics,35 and the engulfment
and cell motility gene 1 (ELMO1), associated with diabetic
nephropathy susceptibility.36 The markers, D15S537 and
D15S659, flanking the peak on chromosome 15q15 were
reported to be in linkage with the autosomal-dominant
renotubular Fanconi’s syndrome,25 which can be related to
muscle weakness.26 Within this region, a few genes involved
in the biosynthesis of creatine could play a role in both
kidney function and/or muscle formation, including the
Calpain 3 (CAPN3),37 the creatine kinase mitochondrial 1A
(CKMT1A),38 and the glycine amidinotransferase (GATM) 38
genes. The two flanking markers for the peak on chromo-
some 16p13 cover a 2 cM region that includes the GLIS
family zinc finger 2 gene (GLIS2 or nephrocystin-7). The
gene is involved in renal tissue architecture in mice, and its
modifications could promote atrophy and development of
glomerular cysts with subsequent nephronophthisis, the first
genetic cause of ESRD.39
The two loci detected on chromosome 22q13 in the
MICROS cohort shared the same LOD-1 region. These loci
could be population specific but a suggestive linkage peak
was detected in the pooled analysis as well. The evidence for
linkage was higher under the multivariable model and when
excluding diabetics, suggesting that these loci should not
be related to diabetic nephropathy. At the lower border of
the LOD-1 region, a little overlap with the LOD-1 interval
reported for linkage to the urinary albumin-to-creatinine
ratio in a multiethnic population, where 59 out of 63
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Figure 1 | LOD scores for SCR on chromosomes 9 (multivariable model) and 11 (sex- and age-adjusted model). On the X axis position is
reported in centiMorgans. Green, red, blue, and black lines indicate results for Vis, ERF, MICROS, and pooled sample, respectively.
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pedigrees were Caucasians,27 was observed. Within this
segment, the MYH9 gene has been recently shown to be
associated with several forms of renal disease in African
Americans: ESRD in nondiabetics,29 focal segmental
glomerulosclerosis,30 and more recently ESRD attributable
to hypertension.32 In a study on hypertensive individuals,
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Figure 2 | LOD scores for SCR on chromosome 16 (sex- and age-adjusted model) and 22 (multivariable model). On the X axis position
is reported in centiMorgans. Green, red, blue, and black lines indicate results for Vis, ERF, MICROS, and pooled sample, respectively.
Table 4 | Association of SNPs within the MYH9 gene with SCR in nondiabetics: results from the three populations and from the
meta-analysisa
SNP Physical Genotype
MICROS ERF VIS Meta-analysise
Name Locationb (RA)c RAFd b (s.e.) P-value RAFd b (s.e.) P-value RAFd b (s.e.) P-value b (s.e.) P-value Het. I 2 (%)
rs735854 35,009,004 C/T(T) 0.33 0.0075 (0.0067) 0.2637 0.36 –0.0007 (0.0082) 0.9315 0.39 –0.0001 (0.0149) 0.9925 0.0037 (0.0049) 0.4447 0.71 0
rs5756129 35,014,038 C/T(C) 0.22 0.0095 (0.0071) 0.1839 0.34 0.0025 (0.0080) 0.7547 0.19 0.0036 (0.0172) 0.8346 0.0062 (0.0051) 0.2259 0.80 0
rs2269529 35,014,300 C/T(C) 0.20 0.0046 (0.0074) 0.5343 0.32 0.0043 (0.0081) 0.5982 0.15 –0.0001 (0.0192) 0.9958 0.0041 (0.0053) 0.4343 0.97 0
rs875726 35,021,915 A/G(G) 0.29 0.0006 (0.0066) 0.9333 0.39 0.0029 (0.0079) 0.7140 0.32 –0.0006 (0.0147) 0.9677 0.0013 (0.0048) 0.7865 0.97 0
rs4821481 35,025,888 C/T(C) 0.04 –0.0162 (0.0161) 0.3168 0.03 –0.0083 (0.0218) 0.7021 0.07 –0.0102 (0.0288) 0.7231 –0.0129 (0.0118) 0.2770 0.95 0
rs1557530 35,035,568 A/G(G) 0.31 0.0022 (0.0067) 0.7380 0.40 0.0011 (0.0078) 0.8913 0.30 –0.0088 (0.0154) 0.5678 0.0007 (0.0048) 0.8829 0.80 0
rs2157256 35,037,607 A/G(A) 0.31 0.0002 (0.0065) 0.9767 0.40 0.0008 (0.0078) 0.9183 0.32 –0.0003 (0.0148) 0.9826 0.0004 (0.0047) 0.9389 1.00 0
rs3830104 35,038,570 C/T(C) 0.05 –0.0031 (0.0138) 0.8225 0.04 0.0087 (0.0186) 0.6412 0.06 0.0180 (0.0301) 0.5497 0.0031 (0.0104) 0.7647 0.76 0
rs8141971 35,041,308 A/G(A) 0.31 0.0000 (0.0065) 0.9953 0.40 –0.0003 (0.0078) 0.9642 0.31 –0.0014 (0.0148) 0.9250 –0.0003 (0.0047) 0.9576 1.00 0
rs2239784 35,044,581 C/T(T) 0.05 –0.0309 (0.0142) 0.0294 0.05 0.0158 (0.0172) 0.3560 0.08 –0.0069 (0.0269) 0.7983 –0.0112 (0.0101) 0.2674 0.11 55
rs1005570 35,045,220 A/G(A) 0.09 0.0087 (0.0107) 0.4146 0.06 –0.0191 (0.0159) 0.2306 0.08 0.0014 (0.0257) 0.9566 0.0002 (0.0084) 0.9794 0.35 5
rs6000239 35,045,975 C/T(T) 0.39 0.0100 (0.0060) 0.0994 0.44 –0.0035 (0.0076) 0.6412 0.35 –0.0146 (0.0140) 0.2971 0.0027 (0.0045) 0.5399 0.16 45
rs4820234 35,059,020 A/G(A) 0.38 0.0082 (0.0063) 0.1879 0.45 –0.0077 (0.0076) 0.3125 0.39 –0.0194 (0.0146) 0.1837 –0.0003 (0.0046) 0.9501 0.10 56
rs1557540 35,062,483 A/G(A) 0.40 0.0120 (0.0062) 0.0548 0.45 –0.0077 (0.0076) 0.3125 0.39 –0.0187 (0.0145) 0.1984 0.0018 (0.0046) 0.6909 0.04 68
rs713839 35,063,884 A/G(A) 0.32 0.0093 (0.0065) 0.1487 0.38 –0.0023 (0.0078) 0.7712 0.32 –0.0150 (0.0150) 0.3164 0.0026 (0.0047) 0.5748 0.24 30
rs739097 35,076,025 A/G(G) 0.40 0.0097 (0.0061) 0.1116 0.45 –0.0077 (0.0076) 0.3125 0.40 –0.0185 (0.0144) 0.1988 0.0008 (0.0045) 0.8621 0.08 61
rs11089788 35,081,047 A/C(C) 0.48 –0.0108 (0.0061) 0.0782 0.48 –0.0109 (0.0075) 0.1465 0.52 –0.0204 (0.0143) 0.1555 –0.0118 (0.0045) 0.0089 0.82 0
rs136206 35,085,444 A/G(A) 0.29 –0.0027 (0.0068) 0.6945 0.41 0.0046 (0.0076) 0.5468 0.31 –0.0272 (0.0157) 0.0838 –0.0021 (0.0048) 0.6664 0.19 40
rs136211 35,088,493 A/G(A) 0.34 –0.0021 (0.0067) 0.7502 0.43 0.0124 (0.0075) 0.1009 0.30 –0.0406 (0.0162) 0.0123 0.0004 (0.0048) 0.9414 0.01 78
rs2294357 35,101,178 C/T(C) 0.14 0.0047 (0.0091) 0.6087 0.05 –0.0075 (0.0169) 0.6550 0.14 0.0142 (0.0203) 0.4842 0.0036 (0.0075) 0.6328 0.70 0
rs5756168 35,104,758 C/T(C) 0.11 0.0284 (0.0097) 0.0034 0.13 0.0144 (0.0108) 0.1839 0.09 –0.0436 (0.0255) 0.0875 0.0173 (0.0069) 0.0127 0.03 72
rs9610498 35,107,685 A/G(G) 0.50 0.0043 (0.0066) 0.5141 0.50 0.0081 (0.0075) 0.2792 0.45 –0.0140 (0.0146) 0.3399 0.0039 (0.0047) 0.4025 0.40 0
aResults are expressed as the linear regression coefficients (b) and s.e., assuming an additive genetic model adjusted for sex, age, and age2. P-values between 0.05 and 0.10 are
represented in italics, those p0.05 in bold.
bLocation is expressed in base pairs.
cGenotype (reference allele).
dRAF, reference allele frequency.
eUnder the hypothesis of homogeneity, a fixed-effect meta-analysis was carried out. However, heterogeneity was assessed as well. The P-value of homogeneity test (Het.) and
the I2 statistics are reported. I2 represents the percentage of variability across studies attributable to heterogeneity rather than chance.33
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Freedman et al.31 reported that the gene was associated with
the urinary albumin-to-creatinine ratio in African Americans
but not in Europeans. Moreover, no association with SCR-
estimated GFR was found in either ethnicity. Having SNP
genotypes available for all study participants, we tested 22
SNPs located inside the gene for association with SCR. One
SNP (the rs1005570) was strongly associated with SCR in
nondiabetics, with a homogeneous effect across the three
populations. Other SNPs were associated with SCR, but only
in MICROS (rs2239784 and rs5756168) or Vis (rs136211).
According to linkage results, associations were stronger in the
MICROS cohort. It is interesting that population specific
significant SNPs were associated with larger variations of
SCR levels than was the meta-analysis significant SNP. In
agreement with the findings of Kao et al.,29 the strength of the
association diminished when diabetics were included. This
could be related to the contamination of other factors acting
as modifiers of SCR levels when diabetes is in place. A direct
comparison with the SNPs analyzed in the cited articles was
not possible because the research focused on susceptibility
alleles present at higher frequencies in Africans than in
Europeans. However, it is worth noting that in our analysis,
the SNPs associated with the trait were located on the 30 side
of the gene, whereas those reported for African Americans in
all earlier studies29–32 were located toward the 50 end. This
observation is important because the MYH9 gene is split
up into large linkage disequilibrium blocks, and the SNPs
detected in our analysis belong to different linkage disequili-
brium blocks than those detected earlier, meaning that there
could be different and population-specific polymorphisms of
the gene affecting renal function. Finally, although recogniz-
ing that SCR is only an approximate indicator of the renal
condition, the replicated association suggests that an altered
status of the gene could modify kidney function also in
healthy individuals not selected for any disease. In fact, in
our study, SCR was measured in the general population and
in all the cohorts SCR values were within the normal range.
For this reason, the functional pathway involving MYH9
in the regulation of renal function needs to be thoroughly
investigated.
In many cases (chromosomes 9p21, 10p11, 11p15,
15q15–21, and 16p13), our linkage signals were reinforced
when removing individuals on anti-hypertensive treatment,
in spite of the power loss because of the exclusion of a
relevant proportion of the sample (in ERF, for instance,
434% participants were on anti-hypertensive treatment).
This effect might be explained by assuming that the exclusion
of treated individuals implied the removal of confounding
factors, so that the peak is the result of more genuine SCR
variations.
Despite the large amount of replication provided, the
observed heterogeneity of heritability and linkage results
across the studied populations could be seen as a weakness of
our study. One reason to explain this heterogeneity could be
found in the use of uncalibrated SCR measurements from the
different studies. However, SCR was standardized on the ranks
of a standard normal distribution within each study, so that
the comparison was homogeneous across studies and the
pooled analysis was not biased. On the other hand, a general
heterogeneity of heritability and linkage findings can be
observed across the literature itself and, in some cases, also
within the same study.5,9 The low power of the Vis pedigree
could also have artificially increased the heterogeneity. Often,
no linkage was detected at locations where substantial signals
were reported in the other two populations. Unfortunately,
reconstructing larger pedigrees for this cohort was not
possible. The most important aspect, however, is that we
are dealing with isolated populations; thus, some hetero-
geneity of results may be expected in advance. In fact,
although isolation increases the within-population environ-
mental and genetic homogeneity, substantial genetic and
environmental differences can occur across isolates. Even in
the absence of founder mutations, different environmental
conditions across isolates can lead to identification of
strong signals in only one population, probably because the
interaction of the variant with the environment modifies
the causal relationship between loci and trait levels. The
three cohorts were heterogeneous with regard to all major
determinants of renal function. Whether such heterogeneity
could bias the results is unlikely because analyses were
population-specific and because, in isolated populations, a
shared environment explains a small, often negligible portion
of trait heritability. This was empirically shown in the
MICROS study,19 and it is because of the homogenous
lifestyle, typical of small, close communities. Chromosomes
9p21 and 11p15 were important exceptions to linkage
heterogeneity. At these locations, signals were present in
more than one population, and a higher LOD score was
shown by the pooled analysis. The extensive comparison with
the literature highlighted that most of our main findings were
probably true positive results and confirmed linkage regions
reported earlier.
In conclusion, our analysis confirmed the important role
of isolated populations in the dissection of quantitative trait
loci involved in the pathophysiology of endophenotypes such
as SCR, at the condition of having large and well-
reconstructed pedigrees. The number of significant loci
detected and, moreover, the large number of replicated loci
reinforce the idea of a complex, polygenic pathway regulating
SCR levels. A thorough investigation of genes within
candidate linkage regions might provide important insights
into the understanding of the biological mechanisms driving
SCR variations.
MATERIALS AND METHODS
Study participants
The EUROSPAN project (http://homepages.ed.ac.uk/s0565445/
index.html), established in 2006, involves five population isolates
from Italy, Croatia, Scotland, Sweden, and the Netherlands.
The project aims to assess the genetic structure of European isolates
and to identify genes affecting common traits, while taking
advantage of genetic and environmental homogeneity of the
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isolates. This work was based on the three isolates in which SCR
was available. The MICROS study40 is a large genetic survey, started
in 2002, which includes 41400 individuals from three isolated
villages of Val Venosta (South Tyrol, Italy), a German-speaking
region at the border with Austria and Switzerland. For geographical,
historical, and political reasons, the area experienced prolonged
isolation from surrounding populations. The ERF study41 is
a family-based study on a Dutch isolated population located
toward the southwest of the Netherlands. The community, fo-
unded in the middle of the 18th century by B150 individuals, was
isolated until recently. The study included 43000 descendants of
22 couples who lived in the area in the 19th century and who had
six or more children baptized in the community church. The Vis
study was carried out in 2003–2004 on 986 unselected, 18- to
93-year-old Croatians recruited from the villages of Vis and
Komiza, on the Dalmatian island of Vis. These settlements
have unique population histories and have preserved their
isolation from other villages and from the outside world for
centuries.42,43
Extensive genealogies were reconstructed for all studies. At
study centers, participants underwent physical examination,
anthropological measurements, and questionnaire interviews to
collect information on health status and lifestyle. Fasting
blood samples were extracted and stored for biochemical
analyses and DNA extraction. SCR (mg per 100 ml) was measured
with the Jaffe´ rate method at each center. All studies received
appropriate ethical approval and all participants gave informed
consent.
Genotype
Genomic DNA was included in a genome-wide scan using 1000
microsatellite markers (short tandem repeat markers, STRs) in
MICROS and 747 microsatellite markers in Vis. Map order
and position were determined from the deCODE Icelandic genetic
map.44 In ERF, the Illumina Infinium Linkage assay (6008 evenly
spaced biallelic markers) was used. Microarray-based genotyping
was carried out at the Centre National de Ge´notypage (France).
For map alignment, the deCODE genetic map was used as a
reference.
Statistical analysis
As all populations had very complex genealogies, not handled by
existing software, pedigrees were split using PedStr (ftp://mga.
bionet.nsc.ru/pedstr/), an algorithm based on the maximization of
the kinship coefficient among individuals included in the same
reduced pedigree.45 Sub-pedigree bit size was restricted to p18,
typically corresponding to o25 individuals. Mendelian inconsis-
tencies were detected using PedCheck46 and PEDSTATS,47 and
removed. Identical-by-descent (IBD) sharing was estimated at 1 cM
intervals using MERLIN,48 which implied the testing of the same
1000 genomic positions in each population and in the pooled
analysis. The pooled IBD matrix was built as a block diagonal
matrix, with the three study-specific IBD matrices on the diagonal,
such that IBD coefficients between individuals from different
populations were equal to 0. To avoid losing linkage information,
genotyped individuals with missing SCR were retained in the
pedigree.
For each population and for the pooled sample, narrow
heritability (h2) and linkage to quantitative trait loci were assessed
by means of a pedigree-based variance components methodology49
using SOLAR 4.1.5 (Southwest Foundation for Biomedical Research,
San Antonio, TX, USA).50 The same software was used for power
estimation. Given that non-normality affects standard error
estimation,51 SCR was normalized by rank transformation. Normal-
ized SCR was first regressed on sex, age, and age
2 (sex- and age-
adjusted model); then body mass index, systolic blood pressure
(mm Hg), anti-hypertensive treatment (yes/no), diabetic status (yes/
no), and smoking habits (ever/never) were included as well
(multivariable model). To account for the possible influence of
anti-hypertensive treatment and diabetes on SCR levels, analyses
were repeated excluding individuals on anti-hypertensive treatment,
diabetics, or both. Between-population homogeneity of participant
characteristics was assessed through w2 and Kruskal–Wallis tests for
categorical and continuous variables, respectively.
LOD scores were estimated as the difference between the log10
likelihood under the alternative hypothesis of linkage and the log10
likelihood under the null hypothesis of no linkage. Empirical LOD
scores were estimated by testing linkage at a fully informative
marker with a completely unlinked trait. The adjustment constant
was the slope of the regression of simulated LOD scores over LOD
scores expected under normality. Empirical P-values were estimated
from the simulated distribution.52 Under generally accepted guide-
lines,28 thresholds for suggestive and significant linkage were set to
1.9 and 3.3, respectively. The LOD-1-supporting interval was
defined as the chromosomal segment within which a decrease of 1
LOD score unit was observed.
The confirmatory analysis of the MYH9 gene was carried out on
the 22 SNPs, located within the gene or its promoter, included in the
Illumina 300 HumanHap SNP Chip, which was available in all the
three populations. All SNPs had a call rate 497%, minor allele
frequency X0.01, and were in the Hardy–Weinberg equilibrium
(P4103). Assuming a genetic additive model, association between
each SNP and SCR was assessed using a linear mixed model,
adjusting for sex, age, and age2, using the nlme53 R package (R
Foundation for Statistical Computing, Vienna, Austria). To account
for relatedness, the variance/covariance matrix was estimated from
the genomic kinship matrix estimated with the GenABEL software
package.54 Evidence from individual studies was pooled using a
fixed effect meta-analysis based on inverse variance weighting.
Between-study heterogeneity was mainly quantified by I2, defined as
the percentage of total variation in study estimates explained by
heterogeneity rather than by sampling error.33
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